👩⚕️ 7,640 ALL kids:
AAP risk ↑ with age & IR/HR (2.2% LR vs 5.8% IR/HR)
🔄 Early AAP rechallenge ↑ 5y EFS (80.1% vs 60.2%)
📉 No rechallenge + high MRD ↓ survival
Early IR/HR no rechallenge: EFS 53.3%
📊 How many patients with lymphoma or myeloma in the US actually benefit from bispecific antibodies?
In our @BloodAdvances letter, we estimate eligibility and response under current FDA labels—and why real-world benefit may be limited.
@THilalMD
https://t.co/RqjOpwIjzh
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.
Read the full review “Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress” by Robin Foà, MD, from @sapienzaroma: https://t.co/tox4rTRrr3
📝 A retrospective analysis published in Leukemia & Lymphoma found that the median OS was not reached in patients with Ph+ B-ALL receiving rituximab vs 14 months in those who did not.
More news: https://t.co/0uF3bb06t5
#allsm#leusm#MedNews#MedEd
📢 Body composition in adult ALL
📊 In our study published at @ESPENorg, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections.
https://t.co/OQViWUy960
@RobertaDemiche3@FernandoGLMD@analymorac@JessicaZaS
🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉
Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario.
🔗 https://t.co/UC5cfv2E4y
Tu aporte será clave para mejorar la atención de LLA en la región.
1/ 📢 Let’s dive into a crucial topic in #Hematology: How do adult regimens compare with pediatric-inspired regimens (PIRs) for Philadelphia-negative ALL? Our study from Mexico offers some insights #ALL@RobertaDemiche3@faustor@rajuan_27@analymorac
https://t.co/b8ydOWFbg5
7/ Conclusions
🔹 Rituximab + TKIs may improve early responses and enhance survival in CD20+ Ph+ ALL without added toxicity.
🔹 These findings are critical for LMICs, where access to newer therapies is limited.
🔹 Future prospective trials are essential to confirm these results.
4/ Results: Molecular Response
Patients receiving rituximab achieved significantly higher 3-month MR4 rates:
🔹 Rituximab: 84%
🔹 No rituximab: 59%
OR: 3.66 (p = .027)
3-month MR4 is critical, as it is linked to improved survival and lower relapse rates in some Ph+ ALL trials.
6/ Dose-dependent effects
✔️ Patients receiving >4 doses of rituximab had significantly better OS.
•Median OS: Not reached (>4 doses) vs. 10 months (≤4 doses).
•HR for mortality: 0.27 (p = .034).
This aligns with prior data emphasizing the importance of adequate dosing.